Does high PD-L1 expression reduce the risk of relapse after definitive surgery in patients with oral cavity cancer?
Background: Uncovering the molecular mechanisms of cancer pathogenesis is crucial for improving survival outcomes. Aims: This study investigates the impact of programmed death ligand 1 (PD-L1) expression on the risk of progression in patients with oral squamous cell carcinoma (OSCC). Materials and m...
| Publicado en: | Acta Oto-Laryngologica Vol. 145; no. 7; pp. 648 - 654 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | equations & formulas pictorial research tables/charts Journal Article |
| Publicado: |
Taylor & Francis Ltd
Jul2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Background: Uncovering the molecular mechanisms of cancer pathogenesis is crucial for improving survival outcomes. Aims: This study investigates the impact of programmed death ligand 1 (PD-L1) expression on the risk of progression in patients with oral squamous cell carcinoma (OSCC). Materials and methods: The retrospective study included adult patients diagnosed with OSCC between January 2012 and December 2023. PD-L1 expression in tissue removed by definitive surgery was evaluated using immunohistochemistry, and tumor proportion score (TPS) and combined positive score (CPS) were calculated. Survival analyses were performed to assess its prognostic implications. Results: Among the 96 patients, TPS and CPS were 20% or above in 52 (54.2%) and 65 (67.7%) cases, respectively. TPS ≥20% was associated with mucosal lip location, earlier disease stage, and decreased risk of progression. The multivariate Cox regression model revealed that stage III/IV disease (HR: 2.176, 95%CI: 1.085–4.376, p =.029) and TPS ≥20% (HR: 0.241, 95%CI: 0.066–0.879, p =.031) were independent risk factors for progression-free survival. Conclusions: The study revealed that increased tumoral PD-L1 expression may reduce the risk of progression in patients with OSCC. Significance: These findings underscore the potential prognostic significance of PD-L1 expression in OSCC following surgical resection. 揭示癌症发病的分子机制, 对于改善生存结果至关重要。 本研究探讨程序性死亡配体1 (PD-L1) 表达对口腔鳞状细胞癌 (OSCC) 患者的疾病进展风险的影响。 本研究回顾性纳入了 2012 年 1 月至 2023 年 12 月期间确诊为 OSCC 的成年患者。采用免疫组化方法评估根治性手术切除组织中 PD-L1 的表达, 并计算肿瘤比例评分 (TPS) 和综合阳性评分 (CPS)。进行生存分析以评估其预后意义。 96 例患者中, 52 例(54.2%)的TPS 和65 例(67.7%)的 CPS 达到或超过 20%。 TPS ≥ 20%与黏膜唇部位、疾病分期较早和进展风险降低相关。多变量Cox回归模型显示, III/IV期疾病(HR: 2.176, 95%CI: 1.085-4.376, p = 0.029)和TPS ≥ 20%(HR: 0.241, 95%CI: 0.066-0.879, p = 0.031)是无进展生存期的独立危险因素。 本研究表明, 肿瘤PD-L1表达的增加可能降低口腔鳞状细胞癌(OSCC)患者的疾病进展风险。 这些发现强调了PD-L1表达在口腔鳞状细胞癌手术切除后的潜在预后意义。 |
|---|